Richard Jacroux - 02 Mar 2026 Form 4 Insider Report for ENDRA Life Sciences Inc. (NDRA)

Role
Chief Financial Officer
Signature
/s/ Richard Jacroux by Coleman Wombwell, attorney-in-fact
Issuer symbol
NDRA
Transactions as of
02 Mar 2026
Net transactions value
$0
Form type
4
Filing time
04 Mar 2026, 21:48:01 UTC
Previous filing
23 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Jacroux Richard Chief Financial Officer 3600 GREEN COURT, SUITE 350, ANN ARBOR /s/ Richard Jacroux by Coleman Wombwell, attorney-in-fact 04 Mar 2026 0002033818

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NDRA Common Stock Award +13,461 +67% $0.000000* 33,461 02 Mar 2026 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Holdings include unvested restricted stock units ("RSUs").
F2 Represents RSUs that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 11, 2026.